The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies
Deadline
Die Frist für den Eingang der Angebote war 2025-11-12.
Die Ausschreibung wurde veröffentlicht am 2025-10-07.
Auftragsbekanntmachung (2025-10-07) Objekt Umfang der Beschaffung
Titel: Toxicity study in naïve mice
Referenznummer: BiconY 01/2025
Kurze Beschreibung:
“The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products,...”
Kurze Beschreibung
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies
Mehr anzeigen
Art des Vertrags: Dienstleistungen
Produkte/Dienstleistungen: Forschungs- und Entwicklungsdienste und zugehörige Beratung📦 Beschreibung
Beschreibung der Beschaffung:
“The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products,...”
Beschreibung der Beschaffung
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies
Mehr anzeigen Dauer
Datum des Beginns: 2025-12-01 📅
Datum des Endes: 2026-05-29 📅
Titel
Los-Identifikationsnummer: LOT-0001
Verfahren Art des Verfahrens
Offenes Verfahren ✅ Administrative Informationen
Frist für den Eingang von Angeboten oder Teilnahmeanträgen: 2025-11-12 11:00:00 📅
Bedingungen für die Öffnung der Angebote: 2025-11-12 11:01:00 📅
Sprachen, in denen Angebote oder Teilnahmeanträge eingereicht werden können: Deutsch 🗣️
Sprachen, in denen Angebote oder Teilnahmeanträge eingereicht werden können: Englisch 🗣️
Mindestzeitraum, in dem der Bieter das Angebot aufrechterhalten muss: 6
Rechtliche, wirtschaftliche, finanzielle und technische Informationen Bedingungen für die Teilnahme
Liste und kurze Beschreibung der Regeln und Kriterien:
“Experience with toxicological studies in mice (minmum 5 reference projects since 1 October 2022).”
Liste und kurze Beschreibung der Regeln und Kriterien:
“3 Audit results from pharma companies or/and regulatory agencies (the last three audits must be specified, whereby the last audit must not be older than 1...”
Liste und kurze Beschreibung der Regeln und Kriterien
3 Audit results from pharma companies or/and regulatory agencies (the last three audits must be specified, whereby the last audit must not be older than 1 October 2022.)
Mehr anzeigen
Liste und kurze Beschreibung der Regeln und Kriterien:
“Declaration that the following requirements are met: GLP Certificate: issued by EMA (European Medicines Agency) or internationally recognized equivalent....”
Liste und kurze Beschreibung der Regeln und Kriterien
Declaration that the following requirements are met: GLP Certificate: issued by EMA (European Medicines Agency) or internationally recognized equivalent. If more than one facility is involved, a separate GLP certifi-cate needs to be available for each.
Mehr anzeigen Bedingungen für den Vertrag
Bedingungen für die Vertragserfüllung:
“Compliance with the European Union Directive (2010/63/ EU) and the relevant implemented national law or if this EU Directive is not applicable to the...”
Bedingungen für die Vertragserfüllung
Compliance with the European Union Directive (2010/63/ EU) and the relevant implemented national law or if this EU Directive is not applicable to the bidder/bidding consortium the relevant comparable rules Place of performance The place of performance must be in EU/EEA including Switzerland, UK, USA and/or Canada.
“#Bekanntmachungs-ID: CXP4D9L52LD#” Körper überprüfen
Name: Vergabekammer des Budnes
Nationale Registrierungsnummer: 022894990
Postanschrift: Kaiser-Friedrich-Straße 16
Postleitzahl: 53113
Postort: Bonn
Region: Bonn, Kreisfreie Stadt🏙️
Land: Deutschland 🇩🇪
E-Mail: vk@bundeskartellamt.bund.de📧
Fax: +492289499163 📠 Verfahren zur Überprüfung
Genaue Informationen über Fristen für Überprüfungsverfahren:
“According to Article 160, Section 3 of the German Act Against Restraint of Competition (GWB), application for review is not permissible insofar as 1. the...”
Genaue Informationen über Fristen für Überprüfungsverfahren
According to Article 160, Section 3 of the German Act Against Restraint of Competition (GWB), application for review is not permissible insofar as 1. the applicant has identified the claimed infringement of the procurement rules before submitting the application for review and has not submitted a complaint to the contracting authority within a period of 10 calendar days; the expiry of the period pursuant to Article 134, Section 2 remains unaffected, 2. complaints of infringements of procurement rules that are evident in the tender notice are not submitted to the contracting authority at the latest by the expiry of the deadline for the application or by the deadline for the submission of bids, specified in the tender notice. 3. complaints of infringements of procurement rules that first become evident in the tender documents are not submitted to the contracting authority at the latest by the expiry of the deadline for application or by the deadline for the submission of bids, 4. more than 15 calendar days have expired since receipt of notification from the contracting authority that it is unwilling to redress the complaint. Sentence 1 does not apply in the case of an application to determine the invalidity of the contract in accordance with Article 135, Section 1 (2). Article 134, Section 1, Sentence 2 remains unaffected.
Mehr anzeigen Informationen über elektronische Arbeitsabläufe
Die elektronische Rechnungsstellung wird akzeptiert
Elektronische Zahlung wird verwendet
Quelle: OJS 2025/S 194-661954 (2025-10-07)